These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20644012)

  • 1. The riddle of nonsustained ventricular tachycardia and sudden cardiac death: are we approaching a solution?
    Patton KK
    Circulation; 2010 Aug; 122(5):449-51. PubMed ID: 20644012
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Braunwald E; Belardinelli L; Hedgepeth CM; Spinar J; Wang W; Qin J; Karwatowska-Prokopczuk E; Verheugt FW; Morrow DA
    Circulation; 2010 Aug; 122(5):455-62. PubMed ID: 20644019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter by Ayalloore and LeLorier regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial".
    Ayalloore SG; LeLorier P
    Circulation; 2011 Apr; 123(14):e404; author reply e405. PubMed ID: 21482971
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter by Madias regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial".
    Madias JE
    Circulation; 2011 Apr; 123(14):e403; author reply e405. PubMed ID: 21482970
    [No Abstract]   [Full Text] [Related]  

  • 5. Ranolazine--treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy.
    Nanda S; Levin V; Martinez MW; Freudenberger R
    Pacing Clin Electrophysiol; 2010 Dec; 33(12):e119-20. PubMed ID: 20345626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New aspects of the epidemiology of sudden cardiac death].
    Willich SN
    Internist (Berl); 1996 Jan; 37(1):12-7. PubMed ID: 8837824
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal programming of implantable cardiac-defibrillators.
    Madhavan M; Friedman PA
    Circulation; 2013 Aug; 128(6):659-72. PubMed ID: 23918187
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials update: sudden cardiac death prevention by implantable device therapy.
    Finch NJ; Leman RB
    Crit Care Nurs Clin North Am; 2005 Mar; 17(1):33-8, x. PubMed ID: 15749399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of prophylactic implantable cardioverter defibrillators to prevent sudden cardiac death.
    Talajic M; Mitchell LB; Hadjis T
    Can J Cardiol; 2000 Jun; 16 Suppl C():26C-8C. PubMed ID: 10887275
    [No Abstract]   [Full Text] [Related]  

  • 10. The contradiction of appropriate shocks in primary prevention ICDs: increasing and decreasing the risk of death.
    Sweeney MO
    Circulation; 2010 Dec; 122(25):2638-41. PubMed ID: 21135359
    [No Abstract]   [Full Text] [Related]  

  • 11. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.
    Buxton AE; Lee KL; Hafley GE; Pires LA; Fisher JD; Gold MR; Josephson ME; Lehmann MH; Prystowsky EN;
    J Am Coll Cardiol; 2007 Sep; 50(12):1150-7. PubMed ID: 17868806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of lipid-altering therapies on ventricular arrhythmias and sudden cardiac death.
    Majmudar MD; Tompkins C; Bachmann JM; Blumenthal RS; Marine JE
    Cardiol Rev; 2009; 17(2):60-9. PubMed ID: 19367147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sudden cardiac death].
    Stoupel E; Jottrand M
    Rev Med Brux; 2001 Dec; 22(6):488-96. PubMed ID: 11811044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological impact of microvolt T-wave alternans in sudden cardiac death primary prevention.
    Daccarett M; Serafimovski N; Machado C
    Int J Cardiol; 2007 Jun; 119(1):127-8; author reply 129-30. PubMed ID: 17049385
    [No Abstract]   [Full Text] [Related]  

  • 15. Suppression of non-sustained ventricular tachycardia with ranolazine: a case report.
    Kaliebe JW; Murdock DK
    WMJ; 2009 Oct; 108(7):373-5. PubMed ID: 19886587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
    Nieminen T; Scirica BM; Pegler JR; Tavares C; Pagotto VP; Kanas AF; Sobrado MF; Nearing BD; Umez-Eronini AA; Morrow DA; Belardinelli L; Verrier RL
    Am J Cardiol; 2014 Jul; 114(1):17-23. PubMed ID: 24852915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.
    Buxton AE; Lee KL; Fisher JD; Josephson ME; Prystowsky EN; Hafley G
    N Engl J Med; 1999 Dec; 341(25):1882-90. PubMed ID: 10601507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sudden cardiac death: who needs an implantable cardioverter-defibrillator and who needs antiarrhythmic drugs?
    Ferrari R; Cinca J; Marber M
    Eur Heart J; 1999 Mar; 20(6):397-8. PubMed ID: 10213339
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
    G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anxiety and anxiety management in patients with implanted cardioverter-defibrillators].
    Ladwig KH; Wirsching C; V Hammerstein A; Danner R; Baumert J; Schmitt C
    Dtsch Med Wochenschr; 2004 Oct; 129(43):2311-5. PubMed ID: 15483771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.